Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 6:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 49 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Ceftriaxone treatment Clear all
Completed Phase 4 Interventional Results available

Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus

NCT01645735
View directory record Official record
Conditions
Infections
Interventions
Ceftaroline fosamil, Ceftriaxone plus vancomycin
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Phoenix, Arizona • Sylmar, California • DeLand, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Sep 30, 2026, 6:54 AM EDT
Completed Phase 2 Interventional Results available

Antibiotic Instillation in Appendicitis

NCT05470517
View directory record Official record
Conditions
Complicated Appendicitis, Acute Appendicitis
Interventions
Ceftriaxone, Intra-peritoneal Fluid Aspiration
Drug · Procedure
Lead sponsor
Johns Hopkins All Children's Hospital
Other
Eligibility
3 Years to 18 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Sep 30, 2026, 6:54 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial Ceftriaxone in Subjects With ALS

NCT00349622
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, ALS
Interventions
ceftriaxone, placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
50
States / cities
Phoenix, Arizona • Davis, California • Fresno, California + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Sep 30, 2026, 6:54 AM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP)

NCT01530763
View directory record Official record
Conditions
Infections, Community Acquired Pneumonia
Interventions
Ceftaroline fosamil, Ceftriaxone, amoxicillin clavulanate
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
2 Months to 18 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Long Beach, California • Oakland, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2015 · Synced Sep 30, 2026, 6:54 AM EDT
Not yet recruiting Phase 4 Interventional

Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia

NCT07537413
View directory record Official record
Conditions
Community Acquired Pneumonia (CAP)
Interventions
Ceftriaxone 1 gram daily, Ceftriaxone 2 grams daily
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Baltimore, Maryland • Glen Burnie, Maryland • Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 30, 2026, 6:54 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae

NCT05294588
View directory record Official record
Conditions
Gonorrhea Male
Interventions
Cefixime, Ceftriaxone, Ciprofloxacin, Neisseria gonorrhoeae strain FA1090, Meningococcal Group B Vaccine, Influenza Vaccine, Tetanus-diptheria Vaccine
Drug · Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Sep 30, 2026, 6:54 AM EDT
Completed Phase 3 Interventional Results available

Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia

NCT00621504
View directory record Official record
Conditions
Bacterial Pneumonia
Interventions
Ceftaroline fosamil for Injection, IV Ceftriaxone, Placebo, Clarithromycin
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
12
States / cities
Los Angeles, California • Pasadena, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Sep 30, 2026, 6:54 AM EDT
Completed Phase 2 Interventional Results available

Randomized, Open-label Phase 2 Study of Oral AZD0914 in the Treatment of Gonorrhea

NCT02257918
View directory record Official record
Conditions
Gonorrhoea
Interventions
AZD0914, Ceftriaxone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Birmingham, Alabama • Indianapolis, Indiana • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Sep 30, 2026, 6:54 AM EDT
Recruiting Early Phase 1 Interventional

Ceftriaxone Pulse Dose for Post-Treatment Lyme Disease

NCT06611111
View directory record Official record
Conditions
Post-Treatment Lyme Disease
Interventions
Ceftriaxone (Rocephin®), Dextrose 5% (D5W)
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
East Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Sep 30, 2026, 6:54 AM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating Efficacy and Safety of Gepotidacin Compared With Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea

NCT04010539
View directory record Official record
Conditions
Gonorrhea
Interventions
Gepotidacin, Ceftriaxone, Azithromycin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
13
States / cities
Los Angeles, California • Palm Springs, California • DeLand, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Sep 30, 2026, 6:54 AM EDT
Terminated Phase 2 Interventional

Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection

NCT01756924
View directory record Official record
Conditions
Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee, Infected Spacers
Interventions
CEM-102, IV or Oral standard of care antibiotics, Rifampin
Drug
Lead sponsor
Arrevus Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Sarasota, Florida • Tamarac, Florida • Savannah, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2019 · Synced Sep 30, 2026, 6:54 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Effect of SYN-004 on the PK of IV Ceftriaxone in Adults With a Functioning Ileostomy

NCT02419001
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Period 1 - Treatment Sequence AB, Period 1 - Treatment Sequence AC, Period 2 - Treatment Sequence AB, Period 2 - Treatment Sequence AC
Drug
Lead sponsor
Theriva Biologics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 27, 2018 · Synced Sep 30, 2026, 6:54 AM EDT
Completed Not applicable Interventional Results available

The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial

NCT02800785
View directory record Official record
Conditions
Appendicitis
Interventions
Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin, Appendectomy
Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
1,552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
25
States / cities
Sylmar, California • Torrance, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Sep 30, 2026, 6:54 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia

NCT02605122
View directory record Official record
Conditions
Community-acquired Bacterial Pneumonia
Interventions
Solithromycin, Standard of Care
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
2 Months to 17 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
21
States / cities
Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Sep 30, 2026, 6:54 AM EDT
Terminated Phase 2 Interventional Results available

Ceftriaxone to PRevent pneumOnia and inflammatTion aftEr Cardiac arresT (PROTECT)

NCT04999592
View directory record Official record
Conditions
Out-Of-Hospital Cardiac Arrest, Pneumonia
Interventions
Standard of care without prophylaxis, Antibiotic prophylaxis
Drug
Lead sponsor
David J. Gagnon
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Sep 30, 2026, 6:54 AM EDT
Terminated Phase 4 Interventional

Noninferiority Comparison of Prophylactic Open Fracture Antimicrobial Regimens

NCT03560232
View directory record Official record
Conditions
Open Fracture, Post-Op Wound Infection
Interventions
Ceftriaxone, Ampicillin/sulbactam, Piperacillin/tazobactam, Cefazolin + Gentamicin, Clindamycin + Gentamicin
Drug
Lead sponsor
Mercy Health Ohio
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Warren, Ohio • Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 11, 2020 · Synced Sep 30, 2026, 6:54 AM EDT
Completed Phase 3 Interventional

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seropositive Chronic Lyme Disease

NCT00001101
View directory record Official record
Conditions
Lyme Disease
Interventions
ceftriaxone, doxycycline
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Sep 30, 2026, 6:54 AM EDT
Completed Phase 3 Interventional Results available

Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia

NCT00509106
View directory record Official record
Conditions
Bacterial Pneumonia
Interventions
Ceftaroline fosamil for Injection, Ceftriaxone, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
622 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Sep 30, 2026, 6:54 AM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Sep 30, 2026, 6:54 AM EDT
Not listed Phase 2 Interventional

Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients.

NCT04869579
View directory record Official record
Conditions
Covid19
Interventions
Selenium (as Selenious Acid), Placebo
Drug · Other
Lead sponsor
CHRISTUS Health
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Longview, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Sep 30, 2026, 6:54 AM EDT
Completed Phase 3 Interventional

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seronegative Chronic Lyme Disease

NCT00000938
View directory record Official record
Conditions
Lyme Disease
Interventions
ceftriaxone, doxycycline
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Sep 30, 2026, 6:54 AM EDT
Terminated Not applicable Interventional Results available

Ceftriaxone in the Management of Bipolar Depression

NCT00566111
View directory record Official record
Conditions
Bipolar Depression
Interventions
ceftriaxone, Saline solution
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Sep 30, 2026, 6:54 AM EDT
Completed Not applicable Interventional Results available

Intravenous Versus Intravenous/Oral Antibiotics for Perforated Appendicitis

NCT00462020
View directory record Official record
Conditions
Perforated Appendicitis
Interventions
5 days of IV antibiotics (ceftriaxone and metronidazole), Home with oral antibiotics when eating (ampicillin/clavulanic acid)
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
Up to 18 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Sep 30, 2026, 6:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Experimental Human Infection With Neisseria Gonorrhoeae (LptA Trial)

NCT04870138
View directory record Official record
Conditions
Gonococcal Infection
Interventions
Azithromycin, Ceftriaxone, Ciprofloxacin, Neisseria gonorrhoeae strain FA1090 A26, Neisseria gonorrhoeae strain FA7527
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 35 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Sep 30, 2026, 6:54 AM EDT